Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Spruce Biosciences (NASDAQ: SPRB), a biopharmaceutical company, announced that its CEO, Javier Szwarcberg, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 2:40 PM ET. The event will focus on Spruce's commitment to developing novel therapies for rare endocrine disorders with unmet medical needs, particularly their product candidate tildacerfont, aimed at treating classic congenital adrenal hyperplasia and a rare form of polycystic ovary syndrome. Interested stakeholders can access the live webcast here, with an archived version available for 30 days on the company’s investor relations website.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 33^rd Annual Healthcare Conference on March 14, 2023 at 2:40 PM ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005548/en/

Media

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@evokecanale.com

media@sprucebiosciences.com



Investors

Xuan Yang

Solebury Trout

(415) 971-9412

xyang@soleburystrat.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

When will Spruce Biosciences present at the Oppenheimer Healthcare Conference?

Spruce Biosciences will present on March 14, 2023, at 2:40 PM ET.

What is the focus of Spruce Biosciences' conference presentation?

The presentation will focus on their development of therapies for rare endocrine disorders, specifically tildacerfont.

How can I access the Spruce Biosciences conference presentation?

You can access the live webcast of the presentation here.

What is tildacerfont being developed for?

Tildacerfont is aimed at treating classic congenital adrenal hyperplasia and a rare form of polycystic ovary syndrome.

Where can I find the archived version of Spruce's conference presentation?

The archived version will be available for 30 days on the company's investor relations website.